PHASE II STUDY OF TUMOR-SPECIFIC IDIOTYPE AND SOLUBLE GM-CSF VACCINATION

肿瘤特异性独特型和可溶性 GM-CSF 疫苗接种的 II 期研究

• 批准号: 7606517
• 负责人: PATRICIA J HOLMAN
• 金额: $ 0.12万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606517
• 关键词: Autologous Stem Cell Transplantation; B-Lymphocytes; Clinical; Computer Retrieval of Information on Scientific Projects Database; Disease remission; Funding; Grant; Granulocyte-Macrophage Colony-Stimulating Factor; Immune response; Immunoglobulin Idiotypes; Institution; Mantle Cell Lymphoma; Molecular; Patients; Phase; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Vaccination; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Evaluate the ability of Id-KLH and GM-CSF to induce cellular and humoral immune responses in patients with low-grade B-cell/mantle cell lymphoma following autologous stem cell transplantation. Evaluate the ability of Id-KLH and GM-CSF to induce or maintain complete clinical or molecular remission in patients with low-grade B-cell/mantle cell lymphoma following autologous stem cell transplantation

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 评估 Id-KLH 和 GM-CSF 在自体干细胞移植后诱导低度 B 细胞/套细胞淋巴瘤患者细胞和体液免疫反应的能力。评估 Id-KLH 和 GM-CSF 在自体干细胞移植后诱导或维持低度 B 细胞/套细胞淋巴瘤患者完全临床或分子缓解的能力